LTL-474 datasheet

Origin	Primary human ovarian cancer	**Histopathology**	High grade serous carcinoma
Year of establishment	2013	**Doubling time**	17-20 days (subrenal capsule grafting site)
Local invasion	Yes, limited	**Metastasis**	No

The LTL-474 (Figure 1) was developed from a patient's primary ovarian high grade serous carcinoma. Histopathologically, it closely resembles the patient's tumor (Figure 2). When grafted under the renal capsules of SCID mice, the LTL-474 shows limited local invasion into adjacent host kidney parenchyma. No distant metastasis was observed in the hosts. The LTL-474 grows well subcutaneously. Viable tissues in early generations have been preserved following by cryopreservation (DMSO), and can be readily resurrected for grafting.



Fig 1. H&E stained LTL-474 tissue sections showing a high grade serous carcinoma grafted under the renal capsules of a NOD SCID mouse.



Fig. 2. Patient's cancer tissue before grafting.

Genetic and epigenetic characteristics

Tissue microarrays containing LTL-474 tissues are in place for screening potential targets upon request.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis (in combination with metastatic tumor lines) and angiogenesis.

2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.

3. Study of mechanisms underlying tumor growth, progression and metatasis.

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013